HCP
PTCT icon

Hexagon Capital Partners’s PTC Therapeutics PTCT Stock Holding History

Hexagon Capital Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-956
Closed -$48.7K – 1296
2025
Q1 		$48.7K Sell
956
-81
-8% -$4.04K 0.01% 475
2024
Q4 		$46.8K Sell
1,037
-8
-0.8% -$342 0.01% 503
2024
Q3 		$38.8K Sell
1,045
-213
-17% -$7.13K 0.01% 503
2024
Q2 		$38.5K Buy
1,258
+190
+18% +$6.16K 0.01% 492
2024
Q1 		$31.1K Buy
1,068
+89
+9% +$2.49K 0.01% 542
2023
Q4 		$27K Buy
979
+557
+132% +$12.7K 0.01% 556
2023
Q3 		$9.46K Buy
422
+253
+150% +$9.41K ﹤0.01% 767
2023
Q2 		$6.87K Sell
169
-2
-1% -$98 ﹤0.01% 835
2023
Q1 		$8.28K Sell
171
-27
-14% -$1.23K ﹤0.01% 776
2022
Q4 		$7.56K Sell
198
-52
-21% -$2.16K ﹤0.01% 803
2022
Q3 		$13K Buy
250
+151
+153% +$7.4K ﹤0.01% 705
2022
Q2 		$4K Buy
+99
New +$3.47K ﹤0.01% 854

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Hexagon Capital Partners's PTCT Position: Q2 2025 in Review

Hexagon Capital Partners sold out of PTC Therapeutics (PTCT) in Q2 2025, closing a stake of 956 shares — an estimated $48.7K sold.

Hexagon Capital Partners first reported a position in PTCT in Q2 2022 and held it in 12 quarters. The position peaked at $48.7K in Q1 2025. 283 funds tracked by Wall St. Rank hold PTCT as of Q2 2025.

  • Hexagon Capital Partners reported no remaining PTC Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 956 PTC Therapeutics shares in Q2 2025, an estimated $48.7K.
  • Hexagon Capital Partners first reported a position in PTC Therapeutics in Q2 2022 and held it in 12 quarters.
  • Hexagon Capital Partners's PTC Therapeutics position peaked at $48.7K in Q1 2025.
  • 283 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.